Pharma BD Deal Intelligence
A near-zero-value JV buyout that consolidated control of a platform BI later grew into a top-10 global animal health business — but the 2004 transaction itself has no isolable financial return
Full analysis, sources & comparables →Boehringer Ingelheim Animal Health Japan Co., Ltd. — the Japan animal health entity that succeeded the post-2004 BI Vetmedica Japan operation following the…
In 2004, Boehringer announced the acquisition of the outstanding shares of Boehringer Ingelheim Shionogi Vetmedica.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
December 2004 announcement; acquired outstanding minority shares; animal health globalization
A near-zero-value JV buyout that consolidated control of a platform BI later grew into a top-10 global animal health business — but the 2004 transaction itself has no isolable financial return
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Boehringer Ingelheim / Boehringer Ingelheim Shionogi Vetmedica (Shionogi stake) (this deal) | 2004 | — | 52 |
| UCB SA / Celltech Group plc | 2004 | $2.7B | 92 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2004 | $7.6B | 84 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Sanofi-Synthelabo SA / Aventis SA | 2004 | $65.0B | 80 |
| Genzyme Corporation / ILEX Oncology Inc. | 2004 | $1.0B | 66 |
| Hospira Inc. / Abbott Hospital Products Division | 2004 | — | 54 |
← Browse all deals · How we score deals
More: 2004 deals